Parsons Capital Management’s GSK GSK Stock Holding History

Parsons Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,718	Closed	-$218K	–	330
2019 Q4	$218K	Buy	+3,718	New	+$207K	0.02%	328
2017 Q3	–	Sell	-4,674	Closed	-$252K	–	359
2017 Q2	$252K	Hold	4,674	–	–	0.03%	318
2017 Q1	$246K	Buy	4,674 +240	+5%	+$12.2K	0.03%	314
2016 Q4	$213K	Buy	4,434 +92	+2%	+$4.54K	0.03%	316
2016 Q3	$234K	Buy	+4,342	New	+$238K	0.03%	300
2015 Q3	–	Sell	-4,822	Closed	-$251K	–	340
2015 Q2	$251K	Sell	4,822 -40	-0.8%	-$2.25K	0.03%	299
2015 Q1	$280K	Buy	4,862 +544	+13%	+$31.2K	0.04%	272
2014 Q4	$230K	Sell	4,318 -896	-17%	-$50.1K	0.03%	308
2014 Q3	$299K	Sell	5,214 -400	-7%	-$24.5K	0.04%	278
2014 Q2	$376K	Buy	5,614 +160	+3%	+$10.8K	0.05%	255
2014 Q1	$364K	Sell	5,454 -40	-0.7%	-$2.7K	0.05%	259
2013 Q4	$367K	Hold	5,494	–	–	0.06%	252
2013 Q3	$345K	Buy	5,494 +216	+4%	+$13.9K	0.06%	242
2013 Q2	$329K	Buy	+5,278	New	+$335K	0.06%	238

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Parsons Capital Management's GSK Position: Q1 2020 in Review

Parsons Capital Management sold out of GSK (GSK) in Q1 2020, closing a stake of 3,718 shares — an estimated $218K sold.

Parsons Capital Management first reported a position in GSK in Q2 2013 and held it in 14 quarters. The position peaked at $376K in Q2 2014. 817 funds tracked by Wall St. Rank hold GSK as of Q1 2020.

Parsons Capital Management reported no remaining GSK position as of Q1 2020 after selling out during the quarter.
Parsons Capital Management sold 3,718 GSK shares in Q1 2020, an estimated $218K.
Parsons Capital Management first reported a position in GSK in Q2 2013 and held it in 14 quarters.
Parsons Capital Management's GSK position peaked at $376K in Q2 2014.
817 funds tracked by Wall St. Rank held GSK as of Q1 2020.

Based on Parsons Capital Management's 13F filing for Q1 2020, filed 5 May 2020.